IND–BMT integration program
E1213955
UNEXPLORED
The IND–BMT integration program was a mid-20th-century New York City subway unification effort that physically and operationally linked the formerly separate IND and BMT divisions into a more cohesive rapid transit system.
All labels observed (1)
| Label | Occurrences |
|---|---|
| IND–BMT integration program canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T16450826 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: IND–BMT integration program Context triple: [Chrystie Street subway project, partOf, IND–BMT integration program]
-
A.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
-
B.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
C.
exagamglogene autotemcel
Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.
-
D.
Cambridge Blood and Stem Cell Biobank
The Cambridge Blood and Stem Cell Biobank is a major research facility that collects, processes, and stores human blood and stem cell samples to support biomedical and translational research.
-
E.
Ajmera Transplant Centre
Ajmera Transplant Centre is a leading organ transplant facility within Toronto General Hospital, specializing in advanced multi-organ transplantation and related clinical care and research.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: IND–BMT integration program Target entity description: The IND–BMT integration program was a mid-20th-century New York City subway unification effort that physically and operationally linked the formerly separate IND and BMT divisions into a more cohesive rapid transit system.
-
A.
BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
-
B.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
C.
exagamglogene autotemcel
Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.
-
D.
Cambridge Blood and Stem Cell Biobank
The Cambridge Blood and Stem Cell Biobank is a major research facility that collects, processes, and stores human blood and stem cell samples to support biomedical and translational research.
-
E.
Ajmera Transplant Centre
Ajmera Transplant Centre is a leading organ transplant facility within Toronto General Hospital, specializing in advanced multi-organ transplantation and related clinical care and research.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.